Karim Fizazi, M.D., from the Université Paris-Sud, and colleagues randomly assigned men with nonmetastatic, castration-resistant prostate cancer and a prostate-specific antigen doubling time of ≤10 months (2:1) to receive either darolutamide (955 participants; 600 mg twice daily) or placebo (554 participants) while continuing androgen-deprivation therapy. The researchers found that in the planned primary analysis, median...
Tag: <span>Prostate cancer</span>
Post
Researchers identify protein that contributes to racial disparities in prostate cancer
Cancer researchers have long known that prostate cancer tends to be more common, more aggressive and more resistant to existing treatments in African-Americans than in Caucasian-Americans, but they’re only beginning to understand why. A Roswell Park Comprehensive Cancer Center study published today points to cellular factors that appear to be driving these disparities—mitochondrial differences that prevent formation of the cancer-killing “death wheel” apoptosome protein complex—and proposes...
Post
PSA screening reduces prostate cancer deaths by 30%
PSA-screening cuts deaths from prostate cancer by some 30%. This is shown by research based on data on 20,000 men monitored for more than two decades. The men’s initially measured PSA level proved highly significant as a predictor of future cancer risk. “This research is important because it shows the long-term effects of an organized...
Post
Protein found more in advanced prostate cancer could be key to preventing drug resistance
A cancer-driving protein is found in the tumours of men with advanced prostate cancer after treatment with hormone drugs, but rarely found in early-stage disease, a new study shows. Image: Prostate cancer carousel (Credit: Mateus Crespo/Prof Johann de Bono, the ICR) The findings of the major study, published in the Journal of Clinical Investigation, confirm...
Post
Prostate cancer: New, quicker test to assess metastasis risk
People with prostate cancer are at risk of metastatic tumors forming. A newly developed test can assess this risk more quickly than existing tests and is also cheaper to run. According to the National Cancer Institute, about 11.2 percent of men will receive a prostate cancer diagnosis at some point in time. In 2015 — the...
Post
Microfluidic Chips to Diagnose and Characterize Cancer: Interview with Prof. Fatih Sarioglu, Georgia Tech
Research into microfluidic devices to aid in cancer diagnosis promises huge leaps in making diagnostics easier and faster. Much of this research is focused on chips that can trap circulating tumor cells (CTCs) which are present in blood samples. CTCs are released from a primary tumor and can form metastases in other sites in the body, a process which is responsible...
Post
Distinguishing fatal prostate cancer from ‘manageable’ cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy. A recent study showed that more than 25 men were being unnecessarily treated with surgery or radiotherapy, for every single life saved. It is believed that success rates could...
Post
Nanoparticle therapeutic restores function of tumor suppressor in prostate cancer
Think of it as a cancer therapy zag instead of a zig. While many groups are developing cancer therapies to target proteins and pathways that are highly active in cancer cells, a team of investigators from Brigham and Women’s Hospital and Boston Children’s Hospital, with collaborators at Memorial Sloan Kettering Cancer Center, is taking a...
Post
New research finds annual well visit increases likelihood of preventive services
A new Harvey L. Neiman Health Policy Institute study assesses the effect of receiving an Annual Wellness Visit (AWV) between 2011 and 2013 on the annual rate of eight preventive services recommended for the Medicare population following the AWV. The study is published online in Preventive Medicine. “The annual wellness visit assesses patients’ health risk...
Post
Hormone therapy can make prostate cancer worse, study finds
CEDARS-SINAI MEDICAL CENTER LOS ANGELES (Sept. 4, 2018) — Scientists at Cedars-Sinai have discovered how prostate cancer can sometimes withstand and outwit a standard hormone therapy, causing cancer to spread. Their findings also point to a simple blood test that may help doctors predict when this type of hormone therapy resistance will occur. Prostate cancer...